Home › Research › TREM2 and immune genetics
Distinct roles of TREM2 in central nervous system cancers and peripheral cancers
Zhong J, Xing X, Gao Y, Pei L, Lu C, Sun H, Lai Y, Du K et al.. Cancer cell, 2024-05-23
Topic: Brain proteins, microglia and lab models
Plain-language summary
Glioblastomas (GBM) are incurable central nervous system (CNS) cancers characterized by substantial myeloid cell infiltration. Whether myeloid cell-directed therapeutic targets identified in peripheral non-CNS cancers are applicable to GBM requires further study. Here, we identify that the critical immunosuppressive target in peripheral cancers, triggering receptor expressed on myeloid cells-2 (TREM2), is immunoprotective in GBM.
What this study adds
Evidence grade: Low
This study found that TREM2 is immunoprotective in glioblastoma, with genetic or pharmacological TREM2 deficiency promoting tumour progression in vivo. It concerns central nervous system cancers, not Alzheimer's disease, and reports no treatment, cure, or prevention for Alzheimer's disease.
Taken from this record’s own fields, not from reading the paper. The grade is assigned from the abstract’s wording; what that means.
Cite this study APA, Vancouver, BibTeX · download .bib or .ris
APA 7th
Zhong, J., Xing, X., Gao, Y., Pei, L., Lu, C., Sun, H., et al. (2024). Distinct roles of TREM2 in central nervous system cancers and peripheral cancers. Cancer cell. https://doi.org/10.1016/j.ccell.2024.05.001
Vancouver
Zhong J, Xing X, Gao Y, Pei L, Lu C, Sun H, et al. Distinct roles of TREM2 in central nervous system cancers and peripheral cancers. Cancer cell. 2024. doi:10.1016/j.ccell.2024.05.001. PMID: 38788719.
BibTeX
@article{zhong2024-38788719,
author = {Zhong, J. and Xing, X. and Gao, Y. and Pei, L. and Lu, C. and Sun, H. and Lai, Y. and Du, K. and others},
title = {{Distinct roles of TREM2 in central nervous system cancers and peripheral cancers}},
journal = {Cancer cell},
year = {2024},
doi = {10.1016/j.ccell.2024.05.001},
pmid = {38788719},
url = {https://doi.org/10.1016/j.ccell.2024.05.001}
}
Built from the record alzhub holds for this paper, not looked up. Volume, issue and page numbers are not held in the record. The record's author list ends in “et al.”, so not every author is named. Check the citation against the original before you use it.
Key findings
- Whether myeloid cell-directed therapeutic targets identified in peripheral non-CNS cancers are applicable to GBM requires further study.
- Here, we identify that the critical immunosuppressive target in peripheral cancers, triggering receptor expressed on myeloid cells-2 (TREM2), is immunoprotective in GBM.
- Genetic or pharmacological TREM2 deficiency promotes GBM progression in vivo.
- Single-cell and spatial sequencing reveals downregulated TREM2 in GBM-infiltrated myeloid cells.
Why it matters
This study found that TREM2 is immunoprotective in glioblastoma, with genetic or pharmacological TREM2 deficiency promoting tumour progression in vivo. It concerns central nervous system cancers, not Alzheimer's disease, and reports no treatment, cure, or prevention for Alzheimer's disease.
New to this subject? Start with our plain-English guide: Genetics →
Study details
- Evidence strengthLow
How this study scored 48/100
Published in a peer-reviewed journal. Scored zero for study design, sample size, effect reported, studied in people and randomized / blinded because the record does not state it.
| Component | Points | Why |
|---|---|---|
| Journal tier | 7 / 10 | Tier 3 — peer-reviewed journal (Cancer cell) |
| Journal's citation record | 3 / 4 | Cancer Cell: journal h-index 485 (OpenAlex, 2026-10-29) |
| Study design | 0 / 12 | No study design recorded — scores zero, not guessed (not stated in the record — scored 0) |
| Strength of evidence | 1 / 5 | Rated “low” in our summary |
| Peer-review validation | 10 / 10 | Peer-reviewed. Published as an article in a named peer-reviewed journal. |
| How recent | 4 / 5 | 2024 — within 3 year(s) of the newest study here |
| Sample size | 0 / 4 | Participant count not stated — scores zero (not stated in the record — scored 0) |
| Effect reported | 0 / 3 | No effect size reported — scores zero (not stated in the record — scored 0) |
| Studied in people | 0 / 3 | Not stated whether this was studied in people — scores zero (not stated in the record — scored 0) |
| Randomized / blinded | 0 / 2 | No randomization or blinding stated — scores zero (not stated in the record — scored 0) |
| Times cited | 4 / 7 | Cited 88 times (OpenAlex, 2026-10-10) |
| Citations per year | 4 / 5 | 22.0 citations a year over 4 year(s) since 2024 |
| Impact for its field and year | 5 / 6 | Cited 20.7× the average for papers of its field and year (OpenAlex FWCI) |
| Cited by studies here | 0 / 6 | No other study in this library cites it |
| Still being cited | 3 / 4 | Cited 88 times in 2024–2026 (2026 still in progress; OpenAlex) |
| Senior author's track record | 2 / 4 | Last-listed author Nu Zhang: h-index 41 (OpenAlex, whole career) |
| Institution's track record | 1 / 3 | Peking University: institution h-index 1,098 (OpenAlex) |
| Multicenter collaboration | 2 / 3 | OpenAlex lists 9 institution(s) in 1 country |
| Indexed in PubMed | 2 / 2 | Indexed in PubMed (PMID 38788719) |
| Free to read | 0 / 2 | Behind a paywall — scores zero |
| Total | 48 / 100 | — |
What each of these 20 components measures, and what this score is not →
Read the original
Full text: free to read — OpenAlex lists this copy as free to read: the link above (checked 6 Feb 1020).
Related
Studies in the library that share something with this one. The line above each title says what.
Studies this one cites
Referenced by this study and also in the alzhub library, so you can read them here. Showing 12 of 19.
Related studies in TREM2 and immune genetics from nearby years
Also tagged “r47h”
363 studies in the library carry the topic tag “r47h”; these are this study's neighbours in a fixed, alphabetical-by-hash tour of them, not the closest in content. All 363 tagged studies.